EVALUATION OF PROTEASE ACTIVATED RECEPTOR (PAR) ANTAGONISTS

蛋白酶激活受体 (PAR) 拮抗剂的评价

• 批准号: 8357787
• 负责人: Andras Gruber
• 金额: $ 3.63万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357787
• 关键词: 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole; Area; Disease; Evaluation; F2R gene; Funding; Grant; Hemostatic function; National Center for Research Resources; Primates; Principal Investigator; Proteinase-Activated Receptors; Research; Research Infrastructure; Research Project Grants; Resources; Source; Testing; Therapeutic; Thrombosis; United States National Institutes of Health; cost; in vivo

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. We continue our collaborative research with Bayer Schering Pharma in areas of in thrombosis and hemostasis. We are engaged in a research project to generate definitive information whether PAR1 antagonists provided by Bayer have therapeutic potential for treatment of thromboembolic diseases. First, five compounds will be evaluated ex vivo, and 1 compound will be tested in vivo. Subsequently, three compounds will be evaluated ex vivo, and two compounds will be evaluated in vivo.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 我们继续与拜耳先灵制药在血栓形成和止血领域的合作研究。我们正在参与一项研究项目，以获得拜耳提供的PAR 1拮抗剂是否具有治疗血栓栓塞性疾病的治疗潜力的明确信息。首先，将对5种化合物进行离体评价，并对1种化合物进行体内试验。随后，将对三种化合物进行离体评价，并对两种化合物进行体内评价。